logo-loader

IDT Corp reports full year higher revenue, but EPS is more than halved

Last updated: 10:05 10 Oct 2018 EDT, First published: 16:54 09 Oct 2018 EDT

Person on smartphone
IDT Corporation provides communications and payment services to individuals and businesses.

IDT Corporation (NYSE:IDT) reported on Tuesday higher full year 2018 revenue but earnings per share fell by more than half as the company tried to cope with what it called "industry-wide headwinds" that affected revenue from its calling services.

Full-year revenue reached $1.55 billion, compared with $1.5 billion a year ago. Earnings per share reached US$0.17 versus the year-ago figure of $0.35. 

Fiscal fourth-quarter revenue for the period ended July 31 reached $392.6 million, slightly below the same period last year of $395 million. But EPS came in at US$0.33, from a loss in the same quarter a year ago of US$$0.41.

Shares surged 25% to $6.63 in morning trading.

READ: Allot Communications study shows widespread consumer demand for more Internet of Things security

"The resilience in many of our core offerings also collectively increased profitability despite facing industry-wide headwinds for paid voice minutes," said IDT chief executive Shmuel Jonas.

"The need for additional capital to invest in our growth initiatives as they scale and the current low valuation of the company prompted IDT's Board of Directors to discontinue our quarterly dividend and execute a stock buyback program," he added.

IDT's flagship BOSS Revolution calling service, which accounted for over 90% of Retail Communications' revenue in 4Q2018 and full fiscal year 2018, continued to be negatively impacted by persistent, market-wide trends including the proliferation of unlimited calling plans offered by wireless carriers, the company said.

IDT Corporation provides communications and payment services to individuals and businesses. The company is based in Newark, New Jersey.

--Updates share price--

Reporting by Rene Pastor, contactable on rene.pastor@proactiveinvestors.com

BenevolentAI advances novel ulcerative colitis treatment through Phase 1a trial

BenevolentAI (OTC:BAIVF) chief scientific officer Dr Anne Phelan joins Proactive's Stephen Gunnion with positive safety data from the Phase 1a, first-in-human, clinical study of BEN-8744 in healthy volunteers. Phelan explained that BEN-8744 is a potent, selective PD10 inhibitor, uniquely...

1 hour, 39 minutes ago